GENSIGHT BIOLOGICS S.A. (EPA:SIGHT)

BRIEF

published on 09/17/2024 at 14:45, 2 months 4 days ago

Goldman Sachs sells its GENSIGHT BIOLOGICS SA shares

Euronext Paris Goldman Sachs Crossing Thresholds Transfer Of Shares GenSight Biologics
BRIEF

published on 09/17/2024 at 14:45, 2 months 4 days ago

Goldman Sachs vend ses actions GENSIGHT BIOLOGICS S.A.

Euronext Paris Franchissement De Seuils Goldman Sachs Cession D'actions GenSight Biologics
PRESS RELEASE

published on 09/17/2024 at 14:40, 2 months 4 days ago

Franchissement de seuils
Déclaration de franchissement de seuils par The Goldman Sachs Group, Inc. concernant GENSIGHT BIOLOGICS S.A. sur Euronext Paris

Euronext Paris Déclaration The Goldman Sachs Group Franchissement De Seuils GenSight Biologics
BRIEF

published on 07/23/2024 at 07:35, 3 months 29 days ago

GenSight Biologics Reports Financial Position and Business Progress

Gene Therapy Financial Update GenSight Biologics LUMEVOQ Early Access Program
BRIEF

published on 07/23/2024 at 07:35, 3 months 29 days ago

GenSight Biologics présente sa situation financière et ses progrès commerciaux

Thérapie Génique Mise À Jour Financière Produits Biologiques GenSight LUMEVOQ Programme D'accès Anticipé
PRESS RELEASE

published on 07/23/2024 at 07:30, 3 months 29 days ago

Informations privilégiées / Communiqué sur comptes, résultats
GenSight Biologics publie sa position de trésorerie au 30 juin 2024, et fait le point sur ses activités. La trésorerie s'élève à 6,9 millions d'euros, suffisante jusqu'au quatrième trimestre 2024

Trésorerie GenSight Biologics Thérapies Géniques Activités LUMEVOQ
PRESS RELEASE

published on 07/23/2024 at 07:30, 3 months 29 days ago

Inside Information / News release on accounts, results
GenSight Biologics reports cash position of €6.9 million as of June 30, 2024, with potential over 100 vials available upon Q3 resumption of early access program. Company confirms sufficient working capital and successful blending step for LUMEVOQ drug product

Working Capital Business Update Cash Position GenSight Biologics LUMEVOQ Drug Product
BRIEF

published on 07/11/2024 at 07:35, 4 months 10 days ago

GenSight Biologics lance une newsletter destinée aux investisseurs particuliers

Investisseurs Particuliers Thérapie Génique LUMEVOQ® Optogénétique Mises À Jour Financières
BRIEF

published on 07/11/2024 at 07:35, 4 months 10 days ago

GenSight Biologics Launches Newsletter for Retail Investors

Financial Updates Gene Therapy Retail Investors LUMEVOQ® Optogenetics
PRESS RELEASE

published on 07/11/2024 at 07:30, 4 months 10 days ago

Informations privilégiées / Autres communiqués
GenSight Biologics lance une lettre d'information destinée aux investisseurs particuliers en France, présentant des actualités et des informations sur la société et ses projets innovants

Investisseurs Particuliers GenSight Biologics Thérapies Géniques Maladies Neurodégénératives Lettre D'information

Published on 11/21/2024 at 16:30, 1 hour 8 minutes ago

The Rise of DINKs: Dual-Income Couples Without Kids Redefine Financial Priorities in America
Published on 11/21/2024 at 16:01, 1 hour 37 minutes ago

Career Certified Extends Its Investment in the Fast-Growing Architecture, Engineering, and Construction (AEC) Professionals Market with Acquisition of My Contractors License
Published on 11/21/2024 at 16:00, 1 hour 38 minutes ago

Financial Independence Group Announces Exclusive Partnership With Power of Zero and Tax-Free Retirement Expert David McKnight
Published on 11/21/2024 at 16:00, 1 hour 38 minutes ago

Wiz Acquires Dazz to Revolutionize Cloud Security Remediation
Published on 11/21/2024 at 16:00, 1 hour 38 minutes ago

Isaac Ullatil Joins Wellstack Board of Directors

View all ACCESSWIRE

Published on 11/21/2024 at 17:06, 32 minutes ago

Original-Research: PORR AG (von Montega AG): Kaufen
Published on 11/21/2024 at 17:02, 35 minutes ago

Original-Research: SBF AG (von Montega AG): Kaufen
Published on 11/21/2024 at 17:01, 36 minutes ago

Original-Research: Delticom AG (von Montega AG): Kaufen
Published on 11/21/2024 at 16:00, 1 hour 38 minutes ago

Director/PDMR Shareholding
Published on 11/21/2024 at 15:41, 1 hour 56 minutes ago

Edison issues report on Murray Income Trust (MUT)

View all EQS

Published on 11/21/2024 at 06:58, 10 hours 40 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 10 hours 40 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 10 hours 40 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 21 hours 30 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 22 hours 18 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE

News